Table 1.
Main characteristics of the included studies
| Study ID | Year | Country | Cancer | Number | Tumor stage (I/II/III/IV) | Sample | Assay | Cutoff value | Multivariate analysis | Survival | HR | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Irino et al13 | 2014 | Japan | ESC | 105 | 52/53 (I–II/III) | Tissue | IHC | IRS >1 | No | OS | SC | Up to 60 |
| Ding et al22 | 2003 | Japan | ESC | 96 | 50/46 (I–II/III–IV) | Tissue | IHC | IRS ≥8 | No | OS | SC | Up to 100 |
| Shi et al23 | 2015 | People’s Republic of China | ESC | 153 | I–III | Tissue | IHC | IRS ≥8 | No | OS | SC | Up to 60 |
| Liu et al24 | 2013 | People’s Republic of China | ESC | 184 | I–III | Tissue | IHC | IRS ≥3 | No | OS | R | Median 48.6 |
| Song et al25 | 2011 | People’s Republic of China | ESC | 174 | 122/62 (I–II/III) | Tissue | IHC | >10% of cells stained | Yes | OS | SC | Up to 33 |
| Liu et al26 | 2010 | People’s Republic of China | Breast | 200 | 177/23 (I–II/III–IV) | Tissue | IHC | IRS ≥6 | No | OS | SC | Median 88 |
| Andre et al27 | 2006 | France | Breast | 142 | 93/49 (I–II/III) | Tissue | IHC | IRS ≥3 | Yes | OS, DFS | R | Median 156 |
| Cabioglu et al16 | 2007 | USA | IBC | 44 | 44 (III) | Tissue | IHC | >50% of cells stained | No | OS | SC | Median 46.5 |
| Sun et al28 | 2015 | People’s Republic of China | NSCLC | 90 | 39/51 (I–II/III–IV) | Tissue | IHC | IRS ≥6 | No | OS | SC | Median 32.5 |
| Itakura et al19 | 2013 | Japan | Lung | 120 | 69/51 (I–II/III–IV) | Tissue | IHC | Median | No | OS, RFS | R | NR |
| Günther et al29 | 2005 | Germany | Colorectal | 99 | 40/59 (I–II/III–IV) | Tissue | IHC | IRS ≥1 | No | OS | R | Median 64 |
| Schimanski et al18 | 2005 | Germany | Colorectal | 96 | 46/50 (I–II/III–IV) | Tissue | IHC | IRS ≥2 | No | OS | SC | Up to 36 |
| Zhou et al12 | 2013 | People’s Republic of China | Gastric | 133 | 50/83 (T1–2/T3–4) | Tissue | IHC | Mean | Yes | OS | SC | Median 43 |
| Ishigami et al30 | 2007 | Japan | Gastric | 224 | 120/124 (I–II/III–IV) | Tissue | IHC | Mean | No | OS | R | Up to 60 |
| Ma et al31 | 2015 | People’s Republic of China | Gastric | 122 | 61/61 (0–II/III–IV) | Tissue | IHC | >50% of cells stained | No | OS | R | Up to 125 |
| Zhang et al32 | 2015 | People’s Republic of China | Gastric | 90 | 29/61 (I–II/III–IV) | Tissue | IHC | >50% of cells stained | Yes | OS | R | Median 25 |
| Deguchi et al33 | 2010 | Japan | Gastric | 72 | 46/36 (T1–2/T3–4) | Tissue | IHC | NR | No | OS | SC | Up to 120 |
| Kwak et al34 | 2005 | Korea | Gastric | 307 | 190/117 (I–II/III–IV) | Tissue | IHC | Moderate staining | No | OS | SC | Median 67 |
| Mashino et al35 | 2002 | Japan | Gastric | 64 | 44/20 (I–IIIa/IIIb–IV) | Tissue | IHC | Strongly/weakly stained | No | OS | SC | Median 21.5 |
| Xia et al15 | 2017 | People’s Republic of China | MRCC | 110 | 51/59 (I–III/IV) | Tissue | IHC | NR | Yes | OS, PFS | R | Median 23.5 (OS), 9.8 (PFS) |
| Cheng et al36 | 2015 | People’s Republic of China | EOC | 30 | 12/18 (I–II/III–IV) | Tissue | IHC | IRS ≥4 | Yes | OS | SC | Median 32 |
| Kodama et al37 | 2007 | Japan | Cervical | 174 | 92/82 (IB–IIB) | Tissue | IHC | >50% of cells stained | No | OS, DFS | SC | Median 56.5 |
| Pitkin et al38 | 2007 | UK | Tonsillar | 84 | 36/48 (I–III/IV) | Tissue | IHC | >33% of cells stained | No | OS, RFS, DSS | SC | Median 33 |
| Xia et al39 | 2015 | People’s Republic of China | OSSC | 60 | 36/24 (I–II/III–IV) | Tissue | IHC | Median | Yes | OS | SC | Up to 80 |
| Tsuzuki et al40 | 2006 | Japan | OOSCC | 90 | 29/61 (I–II/III–IV) | Tissue | IHC | >33% of cells stained | Yes | OS, DFS | SC | 30–60 |
| Mburu et al17 | 2012 | USA | SCCHN | 47 | 13/30 (I–II/III–IV) 4 (unstaged) | Tissue | IHC | Median | Yes | OS, PFS | R | Up to 120 |
| Kühnelt-Leddihn et al41 | 2012 | Austria | PCM | 38 | NR | Tissue | IHC | NR | No | OS, PFS | SC | Up to 120 (OS), 60 (PFS) |
| Nakata et al14 | 2008 | Japan | Pancreatic | 89 | 82/7 (I–II/III–IV) | Tissue | IHC | Strongly/weakly stained | Yes | OS | R | Up to 120 |
| von Hardenberg et al42 | 2014 | Germany | UCB | 119 | 45/74 (T1–2/T3–4) | Tissue | IHC | IRS ≥2 | No | DSS | R | Median 31 |
| Zhou43 | 2013 | People’s Republic of China | UCB | 57 | 23/34 (T1–2/T3–4) | Tissue | IHC | IRS ≥4 | No | RFS | SC | Median 43 |
Abbreviations: DFS, disease-free survival; DSS, disease-specific survival; EOC, epithelial ovarian carcinoma; ESC, esophageal squamous cell carcinoma; IBC, inflammatory breast cancer; IHC, immunohistochemistry; IRS, immunoreactivity score; MRCC, metastatic renal cell carcinoma; NR, not reported; NSCLC, non-small-cell lung cancer; OOSCC, oral and oropharyngeal squamous cell carcinoma; OS, overall survival; OSSC, oral squamous cell carcinoma; PCM, primary cutaneous melanoma; PFS, progress-free survival; R, reported; RFS, recurrence-free survival; SC, survival curve; SCCHN, squamous cell carcinoma of the head and neck; UCB, carcinoma of the bladder.